Search

The article discusses research on pediatric rheumatology. It references various studies including "Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis" and "Disease activity, severity, and damage in the UK juvenile-onset systemic lupus erythematosus cohort" published in "Arthritis and Rheumatism," and "Preventing coronary artery abnormalities: a need for earlier diagnosis and treatment of Kawasaki disease" published in "Pediatric Infectious Disease Journal."

The article discusses several studies on pediatric rheumatology. One study examined the rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Another presented a clinical analysis of macrophage activation syndrome in pediatric patients with autoimmune diseases. A longitudinal study of the Pediatric Rheumatology International Trials Organization (PRINTO) on growth and puberty in juvenile systemic lupus erythematosus is included.

The article offers information on several studies related to pediatric rheumatology. A study assessed the cardiovascular health of asymptomatic patients affected by juvenile-onset systemic and localized scleroderma. Another research examined an open-label and midstage study analyzing the preliminary safety and dosing of canakinumab in patients affected with systemic juvenile idiopathic arthritis.

The article presents three clinical studies on pediatric rheumatology. One study investigates the therapeutic effect of rituximab in patients with juvenile idiopathic arthritis (JIA). A retrospective study seeks to know when it is appropriate to withdraw anti-tumor necrosis factor agents in patients whose JIA is in remission. Another study provides valuable data on epidemiology of generalized joint laxity (hypermobility) in fourteen-year-old children from Great Britain.

The article discusses various studies in pediatric rheumatology. It includes a study by P. A. Nigrovic et al that investigated the efficacy of anakinra as first line disease-modifying therapy in systemic juvenile idiopathic arthritis that supports further exploration of the drug for such indication. D. Guseinova et al presented European and Latin American demographic comparison of clinical features and drug therapies for patients with juvenile dermatomyositis.

The article offers information on research studies on pediatric rheumatology, published in medical journals as of May 2010. A comparison between clinical and ultrasound-determined synovitis in juvenile idiopathic arthritis (JIA) was reported by O. Epis et al. The effects of etanercept treatment on health-related quality of life (HRQoL) in JIA patients are investigated by F. H. Prince et al. A cross-sectional study was done by K. Coyle et al, on the relationship between metabolic abnormalities and cardiovascular risk factors in children with myositis.

The article presents abstracts on pediatric rheumatology which include the effectiveness and safety of etanercept in juvenile idiopathic arthritis, the development of premature atherosclerosis in pediatric systemic lupus erythematosus (SLE) and the potential of adipokines as novel biomarkers in paediatric SLE.

This article discusses studies related to pediatric rheumatology. A study examined the outcomes of patients treated with methotrexate for juvenile idiopathic arthritis (JIA). Results showed that there was an association between an early response to treatment and long-term prognosis among patients with JIA. One study found that antiphospholipid antibodies (aPL) can be used as a marker for poor prognosis in children with systemic lupus erythematosus (SLE). Another study recommended some measures for managing cardiovascular risk factors in SLE patients.

This section provides summaries of research on pediatric rheumatology. The first paper detailed the clinical features of children with Henoch-Schönlein purpura in the Netherlands. The second paper examined the effectiveness of the combination of infliximab and methotrexate in treating adults with rheumatoid arthritis. Another study investigated the evidence that the measles, mumps, and rubella vaccination alters disease activity in juvenile idiopathic arthritis.

The article presents summaries of studies on pediatric rheumatology including "Interleukin 18 as a marker of disease activity and severity in patients with juvenile idiopathic arthritis," by A. P. Lotito, A. Campa, C. A. Silva et al, "Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease," by J. W. Newburger, L. A. Sleeper and B. W. McCrindle et al, and "The impact of a coordinated transitional care programme on adolescents with juvenile idiopathic arthritis," by J. E. McDonagh, T. R. Southwood and K. L. Shaw.

The author comments on the paper "Treatment of Autoinflammatory Diseases: Results From the Eurofever Registry and a Literature Review," by N. Ter Haar, H. Lachmann, S.Özen, and others, which appeared in the periodical "Annals of the Rheumatic Diseases" in 2013. The study evaluated the response to treatment of autoinflammatory diseases using the Eurofever Registry, an web-based registry hosted at the Paediatric Rheumatology International Trials Organization website.

The article offers information on several studies in pediatric rheumatology. One study examined early predictors of juvenile sacroiliitis in enthesitis-related arthritis (ERA) and examined the prevalence of sacroliitis detectable by magnetic resonance imaging. Another study investigated the benefits of ankle ultrasound in evaluating ankle disease in juvenile idiopathic arthritis (JIA). One study proposed the creation of transition clinics to help children with JIA to move from pediatric to adult rheumatology treatment setting.

The article discusses two studies about pediatric rheumatology published in medical journals. The first study reviewed cases of Lyme arthritis in children at a tertiary referral center between 1996 and 2007 and the outcomes, particularly their response to antibiotics. The second is a randomized clinical trial which examined the difference between methotrexate withdrawal at six and 12 months in patients with juvenile idiopathic arthritis who are in clinical remission.

The article features medical studies concerning pediatric rheumatology. A study in Turkey assessed the incidence of tuberculosis in children receiving anti-tumor necrosis factor treatment for juvenile idiopathic arthritis (JIA). Another study assessed the effectiveness and toxicity of methotrexate in JIA.

The article deals with two studies concerning pediatric rheumatology. The first study examined the long-term safety and efficacy of etanercept in children with selected categories of juvenile idiopathic arthritis, published in a 2009 issue of "Arthritis & Rheumatology." The second study, which was published in a 2009 of the "Journal of Rheumatology," assessed ultrasound findings in clinical swollen ankles.

The article presents medical studies on pediatric rheumatology published in medical journals in 2008 and 2009. A study by F. Falcini and colleagues examined the effectiveness and side effects of mycophenolate mofetil when used to treat children with systemic lupus erythematosus. Another study identified features that would predict a good response to methotrexate, a disease-modifying anti-rheumatic drug, in the treatment of juvenile idiopathic arthritis.

A review of several articles about pediatric rheumatology is presented. It includes "Epidemiology of Juvenile Idiopathic Arthritis in a Multiethnic Cohort: Ethnicity As a Risk Factor," "Autologous Stem Cell Transplantation in Children With Severe Progressive Systemic or Polyarticular Juvenile Idiopathic Arthritis: Long-Term Follow-Up of a Prospective Clinical Trial" and "Clinical Features and Outcome of Pediatric Wegener's Granulomatosis."

The article comments on several studies concerning pediatric rheumatology. They include "Composition of Calcifications in Children With Juvenile Dermatomyositis: Association With Chronic Cutaneous Inflammation," "Systemic Sclerosis in Childhood: Clinical and Immunologic Features of 153 Patients in an International Database," and "The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)-Clinical Characteristics of Children Recruited Within the First 5 Years."

Presents citations and notes of clinicians on several studies concerning pediatric rheumatology. "B Lymphocyte Depletion Therapy in Children With Refractory Lupus Erythematosus," by S. D. Marks et al; "The Pediatric Rheumatology International Trials Organization Criteria for the Evaluation of Response to Therapy in Juvenile Systemic Lupus Erythematosus: Prospective Validation of the Disease Activity Core Set," by N. Ruperto et al; "Expression of Human Endogenous Retrovirus HERV-K18 Superantigen Is Elevated in Juvenile Rheumatoid Arthritis," by J. Sicat et al.

This article focuses on various studies related to pediatric rheumatology. One study is "Diagnostic Accuracy of Anti-Cyclic Citrullinated Peptide Antibodies in Juvenile Idiopathic Arthritis," by O. Kasapcopur, S. Altun and M. Aslan. The primary objective of the present study was to correlate serum anti-cyclic citrullinated peptide antibody levels with juvenile idiopathic arthritis subtypes and an erosive disease course. Another study is "Thalidomide for Severe Systemic Onset Juvenile Rheumatoid Arthritis: A Multicenter Study," by T.J. Lehman, S.J. Schechter and R.P. Sundel.

The article reviews the study "International Consensus for Provisions of Quality-Driven Care in Childhood-Onset Systemic Lupus Erythematosus" by M. C. Hollander et al., published in the journal "Arthritis Care & Research (Hoboken) in 2013. The study utilized a structured consensus formation methodology. The consensus reached include having an annual eye screening for systemic lupus erythematosus (SLE) patients, comanagement with a nephrologist, and regular education on cardiovascular risk.

The article reviews the study "Paediatric Rheumatology Practice in the UK Benchmarked Against the British Society for Paediatric and Adolescent Rheumatology/Arthritis and Musculoskeletal Alliance Standards of Care for Juvenile Idiopathic Arthritis" by A. Kavirayani et al., published in "Rheumatology (Oxford)" in 2013. The study compared the clinical practice in Great Britain with the standards of care for patients with juvenile idiopathic arthritis (JIA) by examining access to care.

The author comments on the paper "Adding to complexity: Comorbidity in paediatric rheumatic disease," by E. M. Smith and colleagues, published in "Rheumatology." Renal comorbidities are more common in juvenile-onset systemic lupus erythematosus (JSLE). Patients with systemic-onset juvenile idiopathic arthritis (JIA) have the risk of increased carotid intima-media thickness (CIMT).

The article discusses research on health related quality of life (HRQoL) of patients with active juvenile dermatomyositis (JDM) in the Pediatric Rheumatology International Trials Organisation. It references a study by M. T. Apaz et al, published in a 2009 issue of "Arthritis Rheumatology." The study revealed that there was a significant improvement in HRQol in patients who responded to therapy and the factors that lead to weak physical wellbeing were parents' assessment to their children.

The article presents several published research on the subject of pediatric rheumatology. One of the studies found that health-related quality of life in children and adolescents with juvenile idiopathic arthritis (JIA) can be measured using the Juvenile Arthritis QoL Questionnaire. Another study claims that important for parents to recognize that, when acting as proxies to report the heath of adolescent children with JIA, their estimation of their children's pain may not always be accurate.

Discusses several research on pediatric rheumatology published in medical journals in 2005 and 2006. Effect of age on prevalence of anti-citrullinated protein/peptide antibodies in juvenile idiopathic arthritis; Effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids.

Presents abstracts of several articles on pediatric rheumatology. Randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis; Evidence-based use of methotrexate in children with rheumatic diseases.

Cites several issues concerning pediatric rheumatology. Remission in juvenile chronic arthritis; Probability of diagnosing rheumatoid arthritis; Efficacy of etanercept for the treatment of juvenile idiopathic arthritis.

The article discusses research on the effectiveness of biological agents in juvenile idiopathic arthritis (JIA). It references a study by M. H. Otten and colleagues that was published in the November 21, 2012 issue of the "Annals of the Rheumatic Diseases." The researchers indirectly compared efficacy by reviewing available data from randomized controlled trials of biologics in JIA patients and found that head-to-head trials are necessary in pediatric rheumatology.

Presents citations and clinician's notes on pediatric rheumatology. Explanation of the coronary risk factors in Kawasaki disease treated with additional gammaglobulin; Statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young American Heart Association, on the diagnosis, treatment and long-term management of Kawasaki disease; Number of patients used in each citations.

Presents clinicians' notes about pediatric rheumatology. Role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate; Long term prognosis of children born to lupus patients.

Presents a critique on articles regarding pediatric rheumatology published in various medical literature. Use of corticosteroids in the treatment of Kawasaki disease; Mucocutaneous lymph node syndrome in parents and children; Factors related to severe uveitis during diagnosis of children with juvenile idiopathic arthritis.